Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethoxymethane SCHEMBL27820464 | 0.89 | SMN1; SMN2 (0.56) | SMN1; SMN2MAPK1ABCB1CA12CA1 | |
| SCHEMBL28586196 | 0.87 | SMN1; SMN2 (0.65) | SMN1; SMN2MAPK1PTPN1CA12CA1 | |
| SCHEMBL2220154 | 0.85 | PTPN1 (0.51) | SMN1; SMN2MAPK1PTPN1CA12CA1 | |
| SCHEMBL21246942 | 0.82 | L3MBTL1 (0.43) | SMN1; SMN2MAPK1PTPN1L3MBTL1NFE2L2 | |
| Bromomethane SCHEMBL27848237 | 0.82 | SMN1; SMN2 (0.56) | SMN1; SMN2MAPK1CA12CA1CA2 | |
| SCHEMBL25434306 | 0.82 | CA1 (0.61) | SMN1; SMN2MAPK1CA12CA1CA2 | |
| SCHEMBL27753904 | 0.82 | CA1 (0.61) | SMN1; SMN2MAPK1CA12CA1CA2 | |
| SCHEMBL151213 | 0.82 | CA1 (0.61) | SMN1; SMN2MAPK1CA12CA1CA2 | |
| SCHEMBL12129060 | 0.81 | SMN1; SMN2 (0.57) | SMN1; SMN2MAPK1ABCB1CA12CA1 | |
| SCHEMBL2101135 | 0.80 | CA1 (0.62) | SMN1; SMN2MAPK1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113214057-A | Method for synthesizing aromatic aldehyde by Lewis acid catalysis | 西安工程大学 | 2021-08-06 | — | — | CN | claimed |
| CN-113214057-A | Method for synthesizing aromatic aldehyde by Lewis acid catalysis | 西安工程大学 | 2021-08-06 | — | — | CN | disclosed |
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DARPHARMA, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | DARPHARMA, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070155720-A1 | Co-administration of dopamine-receptor binding compounds | DARPHARMA, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| CN-1964713-A | Co-use of dopamine-receptor binding compounds | DARPHARMA INC (US) | 2007-05-16 | — | — | CN | disclosed |
| EP-1699450-A2 | CO-ADMINISTRATION OF DOPAMINE-RECEPTOR BINDING COMPOUNDS | Darpharma, INC. (US) | 2006-09-13 | — | — | EP | disclosed |
| WO-2006012640-A2 | METHOD OF ADMINISTRATION OF DOPAMINE RECEPTOR AGONISTS | DARPHARMA, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20050232870-A1 | Method of treatment of dopamine-related dysfunction | PURDUE RESEARCH FOUNDATION AND UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2005-10-20 | — | — | US | disclosed |
| WO-2005062894-A2 | CO-ADMINISTRATION OF DOPAMINE-RECEPTOR BINDING COMPOUNDS | DARPHARMA, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| US-6916823-B2 | Method of treatment of dopamine-related dysfunction | PURDUE RESEARCH FOUNDATION (US) | 2005-07-12 | — | — | US | disclosed |
| US-6916832-B2 | Chromeno[4,3,2-de]isoquinolines as potent dopamine receptor ligands | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-07-12 | — | — | US | disclosed |
| US-20050080266-A1 | CHROMENO[4,3,2-DE]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-04-14 | — | — | US | disclosed |
| CN-1499968-A | Method of treatment of dopamine-related dysfuction | 普渡研究基金会 | 2004-05-26 | — | — | CN | disclosed |
| EP-1192161-B1 | CHROMENO[4,3,2-DE]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS | PURDUE RESEARCH FOUNDATION (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20020132827-A1 | Using full D1 dopamine receptor agonists in an intermittent dosing protocol with a short, but essential, \"off-period.\ | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-09-19 | — | — | US | disclosed |
| US-6413977-B1 | D1 AGONISTS; CENTRAL AND PERIPHERAL NERVOUS SYSTEM DYSFUNCTIONS; IMPROVING COGNITION AND MEMORY; PARKINSON'S DISEASE, SCHIZOPHRENIA, ATTENTION-DEFICIT HYPERACTIVITY, SUBSTANCE ABUSE, PHYSIOLOGICAL FUNCTION | PURDUE RESEARCH FOUNDATION | 2002-07-02 | — | — | US | disclosed |
| EP-1192161-A2 | CHROMENO[4,3,2-DE]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS | PURDUE RESEARCH FOUNDATION (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000078765-A2 | CHROMENO[4,3,2-de]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS | PURDUE RESEARCH FOUNDATION (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DRD2, DRD1, DRD3 | SMN1; SMN2 1094/4885MAPK1 4026/4885ABCB1 694/4885 |
| US-20050232870-A1 | Method of treatment of dopamine-related dysfunction | DRD2, DRD1, DRD3 | SMN1; SMN2 716/4885MAPK1 1915/4885ABCB1 2822/4885 |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | ADRA1D, DRD2, CHRM3 | SMN1; SMN2 3945/4885MAPK1 3346/4885ABCB1 757/4885 |
| US-20050080266-A1 | CHROMENO[4,3,2-DE]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS | DRD2, COMT, CHRM3 | SMN1; SMN2 1017/4885MAPK1 1677/4885ABCB1 1208/4885 |
| US-20020132827-A1 | Using full D1 dopamine receptor agonists in an intermittent dosing protocol with a short, but essential, \"off-period.\ | DRD2, DRD1, DRD3 | SMN1; SMN2 1004/4885MAPK1 1274/4885ABCB1 1968/4885 |
| US-20070155720-A1 | Co-administration of dopamine-receptor binding compounds | DRD2, DRD1, DRD3 | SMN1; SMN2 1107/4885MAPK1 4013/4885ABCB1 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.